Executive Summary
ViV-TAVI underperforms native-valve TAVI on the metrics that matter — device success dropped to 71.7% vs 87.9% (OR 0.35) and valve embolization quadrupled (3.9% vs 0.8%) in a propensity-matched Brazilian registry of 3,194 patients, the largest ViV-TAVI dataset out of Latin America to date. FDA MAUDE post-market data on the Sentinel cerebral protection system logged 340 reports with 147 removal-difficulty events and 64 device breakages between 2022 and 2026, complicating the routine-use case. Edwards' raised 2026 TAVR guidance and Autus acquisition arrive against this clinical headwind, complicating the case for treating ViV as a casual default and tightening the screws on the lifetime-management debate that ESC 2025 just elevated.
- ViV-TAVI in Brazil: device success 71.7% vs 87.9% for native-valve, embolization OR 4.44 — in-hospital mortality unchanged (Int J Cardiol).
- Sentinel CPS MAUDE 2022–2026: 340 reports, 77.9% malfunctions, 1.5% deaths, 48 cerebrovascular events linked to filter use (Cardiovasc Revasc Med).
- Annals of Thoracic Surgery posts a SAVR-vs-TAVR-vs-medical-management analysis in dialysis patients — the question is whether either intervention beats palliation (Ann Thorac Surg).
- Anteris secured French regulatory clearance for the DurAVR pivotal, expanding the global trial footprint as the stock moved +15.1% intraday (TradingView).
- Pulmonary artery perforation during pre-TEER right heart cath salvaged with ping-pong technique and Amplatzer plug — case report worth keeping on the cath lab whiteboard (JACC Case Reports).
What to watch: Edwards Q2 2026 earnings on July 23 will test whether the raised TAVR guidance survives a market increasingly scrutinizing ViV durability and lifetime-management complexity.
Aortic Valve (TAVR/TAVI)
ViV-TAVI is not the equivalent of native-valve TAVI, and the largest matched Latin American dataset to date makes that explicit. The Brazilian registry of 3,194 patients across 25 centers (retrospective, 2009–2021, propensity-matched to 127 ViV vs 248 NV) found device success fell to 71.7% vs 87.9% (OR 0.35, 95% CI 0.20–0.60) and valve embolization rose to 3.9% vs 0.8% (OR 4.44). Pacemaker rates were lower with ViV (4.7% vs 12.9%) — the expected anatomic finding, as the surgical sewing ring constrains implantation depth and protects the conduction system. Mortality, stroke, bleeding, and vascular complications were statistically indistinguishable in-hospital, but the device-success gap is the headline. ESC 2025 explicitly flags lifetime management as paramount when life expectancy exceeds assumed valve durability, and THV explantation carries 12–17% mortality. The Brazilian data quantifies what guidelines describe in prose: the second valve is the harder valve. [NOTABLE] A 16-point device-success gap argues against treating ViV as a casual default. For the 68-year-old facing a bioprosthetic choice today, ACC/AHA 2020's SAVR preference below age 65 and ESC 2025's threshold of 70 both rest on the assumption that ViV will be a clean rescue — an assumption this registry does not support.
The Annals of Thoracic Surgery dialysis analysis reopens an older but unsettled question: in patients on dialysis with severe AS, neither SAVR nor TAVR has shown a convincing survival benefit over conservative management in most observational series. Both ACC/AHA 2020 and ESC 2025 are silent on dialysis-specific decision-making beyond noting limited life expectancy as a consideration favoring TAVI or palliation.
Edwards' raised 2026 TAVR guidance and Autus deal arrive against this backdrop — the volume story is intact, but the durability story is the long bet.
Mitral Valve (MitraClip, PASCAL, TMVR)
A procedural reminder arrived via JACC Case Reports: a left pulmonary artery perforation during pre-TEER right heart catheterization in an older woman under general anesthesia, presenting as endotracheal bleeding with desaturation. Wedge balloon occlusion controlled bleeding; second femoral access delivered a 12-mm Amplatzer vascular plug via ping-pong guide technique. PA perforation during RHC is rare and lethal — and RHC is routine before TEER for hemodynamic phenotyping and COAPT-criteria documentation (SPAP ≤70 mmHg eligibility). ESC 2025 upgraded TEER for ventricular SMR to Class I, LOE A on the strength of COAPT 5-year data and RESHAPE-HF2; ACC/AHA 2020 holds it at Class IIa. That guideline gap presumes the periprocedural workup is safe. It largely is — but the catheterization pathway carries its own complication profile that neither guideline enumerates. The take-home isn't to abandon RHC: respiratory tract bleeding during pre-procedural workup should trigger PA perforation as the leading diagnosis until proven otherwise.
Tricuspid Valve (TriClip, TTVR)
No new tricuspid trial data today. ESC 2025 endorses transcatheter TV treatment as Class IIa, LOE A based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 carries no recommendation because those trials had not read out. The real-world STS/ACC TVT Registry analysis of 1,034 EVOQUE TTVR procedures showed 98.4% technical success, 3.1% 30-day mortality, and 15.9% new pacemaker rate — better than TRISCEND II on pacemakers, comparable on safety. The surgical comparator remains contemporary isolated TV surgery in earlier-referred patients, where mortality has improved from the historical 8–20% range but still exceeds transcatheter alternatives in matched cohorts.
Surgical vs. Transcatheter Comparisons
The Brazilian ViV-TAVI registry is implicitly a surgical-vs-transcatheter argument carried forward by a decade. Every ViV procedure in this cohort is a downstream consequence of a prior bioprosthetic surgical valve. The 71.7% device success in the ViV arm should inform — not retrospectively justify — today's choice between mechanical valve, biological valve, or TAVR in the index 65–70-year-old patient. The Annals of Thoracic Surgery dialysis analysis reopens an older but unsettled question: in patients on dialysis with severe AS, neither SAVR nor TAVR has shown a convincing survival benefit over conservative management in most observational series. Both ACC/AHA 2020 and ESC 2025 are silent on dialysis-specific decision-making beyond noting limited life expectancy as a consideration favoring TAVI or palliation.
Device & Technology
[NOTABLE] The FDA MAUDE analysis of the Sentinel cerebral protection system (2022–2026, 340 reports) is the most comprehensive post-market dataset on this device to date. Malfunctions dominated at 77.9%, with 147 difficult-removal events, 64 breakages, and 57 positioning problems. Patient injuries accounted for 20.6%, deaths 1.5%, and 48 events involved stroke or cerebrovascular complications — the very outcome the device exists to prevent. MAUDE is voluntary and skewed toward adverse events, so denominator-free incidence cannot be calculated. The signal is procedural: removal difficulty and breakage indicate design and technique optimization remain open. Operators should not over-read these counts as effectiveness failure — PROTECTED TAVR remains the randomized story — but the device is not friction-free.
Regulatory & Policy
Anteris received French regulatory clearance to expand the DurAVR transcatheter heart valve global trial, broadening pivotal enrollment beyond initial geographies. DurAVR is positioned as a single-piece bovine pericardial valve with a biomimetic design; European clearance is a procedural step toward eventual CE mark consideration. Whether DurAVR can differentiate against established balloon-expandable and self-expanding competitors depends on durability and hemodynamic data, neither of which is mature at pivotal scale.
Industry & Market
Edwards Lifesciences raised 2026 TAVR guidance and closed the Autus acquisition, two moves that together signal management confidence in both the core franchise and the platform-extension story. The raised guidance reflects EARLY TAVR's commercial tailwind from ESC 2025's expanded asymptomatic indication (Class IIa) — a guideline shift that, if mirrored in the next ACC/AHA update, materially expands the eligible US population.
Financial Analysis
The Edwards narrative shift is a clean illustration of clinical evidence translating into market signal. EARLY TAVR (NEJM 2024) and the ESC 2025 Class IIa upgrade for asymptomatic severe AS enlarge the addressable population without requiring new technology — pure indication expansion with guideline backing. Anteris's 15.1% single-session move on French clearance is a different signal: micro-cap pivotal-stage volatility on regulatory milestones, not revenue. The structural-heart majors (MDT, ABT, BSX) have been heavily punished over six months despite stable valve fundamentals, suggesting the selling pressure is sector-wide rather than valve-specific. Boston Scientific's 48% six-month decline against a $78 consensus target ($55–$106 range) is the widest dispersion in the group and the cleanest contrarian setup.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $85.96 (-1.70% daily); 6-month +1.94%
- Market cap: $49.5B | P/E trailing 46.46, forward 25.53 | Beta 0.87
- 52-week range: $72.30–$89.44
- Analyst consensus: $96.92 target (range $84–$110, 26 analysts), Buy
- Next earnings: July 23, 2026 — EPS $0.74, Revenue $1.70B
- Commentary: The raised 2026 TAVR guidance plus Autus close mark the third consecutive quarter of management pushing the narrative beyond core franchise. The asymptomatic-AS guideline tailwind from EARLY TAVR is the structural tailwind that justifies the forward multiple. ViV durability risk is the latent counter-story.
Medtronic (MDT)
- Price: $81.67 (-0.32% daily); 6-month -18.09%
- Market cap: $104.9B | P/E trailing 21.9, forward 12.73 | Beta 0.6
- 52-week range: $73.31–$106.33
- Analyst consensus: $98.58 target (range $78–$121, 26 analysts), Buy
- Next earnings: August 18, 2026 — EPS $1.39, Revenue $9.55B
- Commentary: Evolut Low Risk 5-year data underwrites the structural-heart franchise, but six-month underperformance reflects sector rotation rather than valve-specific weakness. Forward P/E under 13 with a Buy consensus is the contrarian-value setup.
Abbott (ABT)
- Price: $91.07 (+0.32% daily); 6-month -24.56%
- Market cap: $158.6B | P/E trailing 25.51, forward 15.02 | Beta 0.62
- 52-week range: $81.97–$139.06
- Analyst consensus: $117.29 target (range $92–$135, 24 analysts), Buy
- Next earnings: July 16, 2026 — EPS $1.28, Revenue $12.53B
- Commentary: MitraClip's ESC 2025 Class I upgrade is the durable franchise tailwind. TriClip lags Edwards' EVOQUE on transcatheter TR replacement but holds first-mover advantage on TEER. The 24.5% drawdown is unexplained by valve fundamentals.
Boston Scientific (BSX)
- Price: $48.55 (-0.61% daily); 6-month -48.26%
- Market cap: $72.2B | P/E trailing 20.31, forward 13.02 | Beta 0.56
- 52-week range: $47.17–$109.50
- Analyst consensus: $78.17 target (range $55–$106, 30 analysts), Strong Buy
- Next earnings: July 29, 2026 — EPS $0.83, Revenue $5.38B
- Commentary: The widest gap to consensus in the group. ACURATE neo2 European data and the Lotus retirement remain in the rearview. Strong Buy consensus at a 60% implied upside reflects either deep value or analyst lag.
Anteris Technologies (AVR.AX)
- Price: AUD $13.80 (+15.10% daily); 6-month +111.01%
- Market cap: $1.3B | Forward P/E -6.33 | Beta 0.73
- 52-week range: $4.68–$13.85
- Analyst consensus: $13.00 target (single analyst)
- Commentary: French regulatory clearance for DurAVR pivotal drove today's move. Pre-revenue micro-cap with binary clinical readouts ahead; the 111% six-month run prices in execution that hasn't yet been delivered at scale.
Market outlook: The structural heart sector splits cleanly into two narratives. The majors (MDT, ABT, BSX) trade as if valve fundamentals don't matter — six-month declines of 18–48% don't square with the strongest guideline tailwinds in a decade (ESC 2025 TAVI age threshold, TEER Class I, transcatheter TR Class IIa). Edwards holds gains because its pure-play valve exposure leaves no other business to drag the multiple. Anteris is the speculative bet on the next-generation aortic platform. The asymmetry between guideline expansion and stock performance in the majors is the trade worth watching.
Clinical Trial Updates
No structural heart trials posted status changes today. The one updated registration was non-valvular (sapablursen in polycythemia vera) and is excluded from this section. Standing landmark trials worth tracking:
- Aortic: [LANDMARK] EARLY TAVR (asymptomatic severe AS) — ESC 2025 already incorporated; ACC/AHA update pending. PARTNER 3 and Evolut Low Risk extended follow-up reads out annually.
- Mitral repair: [LANDMARK] REPAIR-MR comparing TEER to surgery in moderate-risk degenerative MR — the trial that will test whether ESC's Class IIa TEER-for-PMR holds against surgical repair head-to-head.
- Mitral replacement: APOLLO (Intrepid TMVR) and SUMMIT (Tendyne) — both pivotal, both will define whether TMVR has a role beyond TEER-ineligible anatomy.
- Tricuspid repair: [LANDMARK] TRILUMINATE Pivotal extended follow-up; CLASP TR Pivotal (PASCAL) — the comparative-effectiveness question between TriClip and PASCAL remains open.
- Tricuspid replacement: [LANDMARK] TRISCEND II (EVOQUE) — informed ESC 2025 Class IIa; pacemaker and bleeding rates remain the durability-of-benefit question.
Next test for the field: Edwards' July 23 earnings will reveal whether the asymptomatic-AS commercial conversion is accelerating ahead of an ACC/AHA update, and whether ViV-TAVI volumes are moderating as the durability conversation gains traction at the clinical decision point.